ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) COO Brian Dorsey Sells 25,000 Shares

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) COO Brian Dorsey sold 25,000 shares of the company's stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $12.30, for a total value of $307,500.00. Following the completion of the sale, the chief operating officer now owns 6,024 shares in the company, valued at approximately $74,095.20. This represents a 80.58 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

ARS Pharmaceuticals Trading Down 5.9 %

SPRY traded down $0.74 on Friday, reaching $11.90. The stock had a trading volume of 984,298 shares, compared to its average volume of 825,045. The business's 50-day moving average price is $14.62 and its two-hundred day moving average price is $12.34. The company has a market cap of $1.16 billion, a P/E ratio of -23.33 and a beta of 0.88. ARS Pharmaceuticals, Inc. has a 12-month low of $5.02 and a 12-month high of $18.51.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. Cantor Fitzgerald reiterated an "overweight" rating and issued a $30.00 price objective on shares of ARS Pharmaceuticals in a research note on Tuesday, October 8th. Leerink Partners lifted their price objective on ARS Pharmaceuticals from $21.00 to $25.00 and gave the company an "outperform" rating in a research note on Friday, September 20th. Finally, William Blair upgraded ARS Pharmaceuticals to a "strong-buy" rating in a research note on Friday, August 30th. Four investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, ARS Pharmaceuticals presently has an average rating of "Buy" and an average price target of $24.00.

Hedge Funds Weigh In On ARS Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of SPRY. nVerses Capital LLC acquired a new stake in ARS Pharmaceuticals in the third quarter valued at approximately $30,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of ARS Pharmaceuticals by 151.7% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,419 shares of the company's stock valued at $63,000 after buying an additional 4,472 shares in the last quarter. Principal Financial Group Inc. purchased a new position in shares of ARS Pharmaceuticals during the 2nd quarter valued at approximately $87,000. Quarry LP acquired a new stake in ARS Pharmaceuticals in the 3rd quarter valued at $174,000. Finally, TFG Advisers LLC acquired a new position in ARS Pharmaceuticals during the third quarter worth $180,000. Hedge funds and other institutional investors own 68.16% of the company's stock.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.